Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Status and phase: Completed; Phase 1

Conditions: Childhood Burkitt Lymphoma; Childhood Low-grade Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Childhood High-grade Cerebral Astrocytoma; Childhood Supratentorial Ependymoma; Childhood Central Nervous System Germ Cell Tumor; Childhood Infratentorial Ependymoma; Childhood Grade III Meningioma; Recurrent Childhood Cerebral Astrocytoma; Childhood Grade II Meningioma; Childhood Choroid Plexus Tumor; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Medulloblastoma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Visual Pathway and Hypothalamic Glioma; Childhood Spinal Cord Neoplasm; Recurrent Childhood Large Cell Lymphoma; Childhood Grade I Meningioma; Recurrent Childhood Brain Tumor; Childhood Craniopharyngioma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Unspecified Childhood Solid Tumor, Protocol Specific

Treatments: Drug: ispinesib; Other: laboratory biomarker analysis; Other: pharmacological study

Study type: Interventional

Funder types: NIH

Identifiers

NCT00363272

ADVL0517

NCI-2012-01828

CDR0000491407 (Registry Identifier)

U01CA097452 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This phase I trial is studying the side effects and best dose of ispinesib in treating young patients with relapsed or refractory solid tumors or lymphoma. Drugs used in chemotherapy, such as ispinesib, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing

Full description

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose and recommended phase II dose of ispinesib in pediatric patients with refractory solid tumors or lymphoma.

II. Define and describe the toxicities of ispinesib in these patients. III. Characterize the pharmacokinetics of ispinesib in these patients.

SECONDARY OBJECTIVES:

I. Define, preliminarily, the antitumor activity of ispinesib. II. Determine the relationship between CYP3A4 gene polymorphisms and pharmacokinetics in patients treated with this regimen.

OUTLINE: This is a multicenter, dose-escalation study.

Patients receive ispinesib IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of ispinesib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients undergo blood and tumor sample collection periodically for pharmacokinetic and gene polymorphism correlative studies.

After completion of study therapy, patients are followed for 30 days.

Enrollment: 30 patients

Sex: All

Ages: 1 to 21 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Histologically confirmed malignancy at either original diagnosis or relapse, including the following:

  • Solid tumor, including primary CNS tumors

    • Neurologic deficits in patients with CNS tumors must have been relatively stable for ≥ 1 week
    • Patients with CNS tumors must be on stable or decreasing doses of dexamethasone for the past 7 days
    • Histology requirement waived for intrinsic brain stem tumors

  • Lymphoma

• Measurable or evaluable disease

• No known curative therapy or no therapy proven to prolong survival with an acceptable quality of life exists

• Patients with known bone marrow metastases are eligible for study but are not evaluable for hematologic toxicity

  • Not known to be refractory to red blood cell or platelet transfusions

• Karnofsky performance score (PS) 60-100% (> 10 years of age) or Lansky PS 60-100% (≤ 10 years of age)

• Absolute neutrophil count ≥ 1,000/mm³

• Platelet count ≥ 100,000/mm³ (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to study enrollment)

• Hemoglobin ≥ 8.0 g/dL (RBC transfusions allowed)

• Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR creatinine based on age as follows:

  • No greater than 0.8 mg/dL (≤ 5 years of age)
  • No greater than 1.0 mg/dL (6 to 10 years of age)
  • No greater than 1.2 mg/dL (11 to 15 years of age)
  • No greater than 1.5 mg/dL (> 15 years of age)

• Bilirubin ≤ 1.5 times upper limit of normal

• ALT ≤ 45 U/L

• Albumin ≥ 2 g/dL

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No evidence of active graft-vs-host disease

• No uncontrolled infection

• Recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy

• More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)

• More than 1 week since prior growth factors, including those that support platelet or WBC number or function

• At least 1 week since prior biologic agents

• At least 2 weeks since prior local, palliative, small-port external-beam radiotherapy

• At least 6 months since prior total body irradiation (TBI), craniospinal radiotherapy, or radiotherapy to ≥ 50%of the pelvis

• At least 6 weeks since other prior substantial bone marrow radiotherapy (i.e., skull, spine, pelvis, or ribs)

• At least 3 months since prior stem cell transplantation or rescue without TBI

• No other concurrent investigational drugs

• No other concurrent anticancer agents, including chemotherapy, radiotherapy, immunotherapy, or biologic therapy

• No concurrent enzyme-inducing anticonvulsants, including any of the following:

  • Phenytoin
  • Phenobarbital
  • Felbamate
  • Primdone
  • Oxcarbazepine
  • Carbamazepine

• No concurrent agents that inhibit CYP3A4, including any of the following:

  • Itraconazole
  • Ketoconazole
  • Voriconazole

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

Arm I

Experimental group

Description:

Patients receive ispinesib IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.

Treatment:

Other: pharmacological study

Drug: ispinesib

Other: laboratory biomarker analysis